Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.47 |
| ▸ | HSP90AA1 | P07900 | 2/20 | 0.45 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.44 |
| ▸ | LIG1 | P18858 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | HNF4A | P41235 | 1/20 | 0.44 |
| ▸ | MYC | P01106 | 1/20 | 0.43 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.41 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.40 |
| ▸ | TYMS | P04818 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | NR4A1 | P22736 | 1/20 | 0.39 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.39 |
| ▸ | NR4A3 | Q92570 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | GFER | P55789 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31032281 | 1.00 | ALDH1A1 (0.47) | ALDH1A1L3MBTL1LMNAMAPTHSD17B10 | |
| SCHEMBL1759573 | 0.89 | MRGPRX4 (0.51) | ALDH1A1L3MBTL1LMNAMAPTHSD17B10 | |
| SCHEMBL11131477 | 0.83 | AKR1C3 (0.50) | ALDH1A1L3MBTL1LMNAMAPTHSP90AA1 | |
| SCHEMBL21471348 | 0.82 | PARP1 (0.53) | ALDH1A1MAPTHSD17B10ALOX15GAA | |
| SCHEMBL4272994 | 0.82 | ALDH1A1 (0.55) | ALDH1A1L3MBTL1LMNAMAPTHSD17B10 | |
| SCHEMBL4819056 | 0.79 | KEAP1 (0.54) | ALDH1A1GAATYMS | |
| SCHEMBL13190091 | 0.78 | HSD17B10 (0.46) | ALDH1A1L3MBTL1LMNAMAPTHSD17B10 | |
| SCHEMBL7406575 | 0.78 | PTPRC (0.50) | ALDH1A1LMNAMAPTHSD17B10GAA | |
| SCHEMBL31305912 | 0.78 | PTPRC (0.50) | ALDH1A1LMNAMAPTHSD17B10GAA | |
| SCHEMBL7836093 | 0.78 | CYP3A4 (0.57) | ALDH1A1L3MBTL1LMNAHSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 58 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210108245-A1 | Enantioselective Biocatalytic Preparation of 4-Cyano-Substituted 1-Aminoindane and Ozanimod | PHARMAZELL GMBH (DE) | 2021-04-15 | — | — | US | claimed |
| CN-111971398-A | Enantioselective biocatalytic preparation of 4-cyano-substituted 1-aminoindan and azanidod | 泽尔制药有限公司 | 2020-11-20 | — | — | CN | claimed |
| EP-3553179-A1 | ENANTIOSELECTIVE BIOCATALYTIC PREPARATION OF 4-CYANO-SUBSTITUTED 1-AMINOINDANE AND OZANIMOD | Universität Bielefeld (DE) | 2019-10-16 | — | — | EP | claimed |
| JP-58023640-A | — | — | None | — | — | JP | disclosed |
| WO-2025067239-A1 | KINESIN KIF18A INHIBITOR, AND APPLICATION THEREOF | 上海湃隆生物科技有限公司 | 2025-04-03 | — | — | WO | disclosed |
| US-20250017914-A1 | 6-AZA-QUINOLINE DERIVATIVES AND RELATED USES | BLACK DIAMOND THERAPEUTICS, INC. | 2025-01-16 | — | — | US | disclosed |
| EP-4399210-A1 | 6-AZA-QUINOLINE DERIVATIVES AND RELATED USES | Black Diamond Therapeutics, Inc. (US) | 2024-07-17 | — | — | EP | disclosed |
| CN-118159537-A | 6-Aza-quinoline derivatives and related uses | 黑钻治疗公司 | 2024-06-07 | — | — | CN | disclosed |
| EP-3513656-B1 | METHOD FOR INCREASING AMINO ACID CONTENT IN PLANTS | AJINOMOTO KK (JP) | 2023-07-05 | — | — | EP | disclosed |
| WO-2023039505-A1 | 6-AZA-QUINOLINE DERIVATIVES AND RELATED USES | BLACK DIAMOND THERAPEUTICS, INC. (US) | 2023-03-16 | — | — | WO | disclosed |
| CN-115746222-A | Composite water reducing agent and preparation process thereof | 广东六合新型建材有限公司 | 2023-03-07 | — | — | CN | disclosed |
| US-6288099-B1 | COMPOUNDS SUCH AS 8-BROMO-10H-BENZO(4,5)FURO(3,2-B)INDOLE-1-CARBOXYLIC ACID USED TO TREAT DISORDERS ASSOCIATED WITH SMOOTH MUSCLE CONTRATION SUCH AS URINARY INCONTINENCE AND IRRITABLE BOWL SYNDROME | AMERICAN HOME PRODUCTS CORPORATION | 2001-09-11 | — | — | US | disclosed |
| WO-2000034285-A2 | SUBSTITUTED BENZOFURANOINDOLES AND INDENOINDOLES AS NOVEL POTASSIUM CHANNEL OPENERS | AMERICAN HOME PRODUCTS CORPORATION (US) | 2000-06-15 | — | — | WO | disclosed |
| US-6057454-A | USEFUL FOR TREATING OR PREVENTING ALL ISCHAEMIAS (SUCH AS FOCAL OR GLOBAL ISCHAEMIA) RESULTING FROM CEREBROVASCULAR DISORDERS | RHONE-POULENC RORER S.A. (FR) | 2000-05-02 | — | — | US | disclosed |
| US-5902803-A | 5H,10H-imidazo 1,2-a!indeno 1,2-e!pyrazin-4-one derivatives, preparation thereof, and drugs containing said derivatives | RHONE-POULENC RORER S.A. (FR) | 1999-05-11 | — | — | US | disclosed |
| JP-S5823640-A | PREPARATION OF 4-BENZOYL-INDANONES | TAKEDA CHEM IND LTD | 1983-02-12 | — | — | JP | disclosed |
| US-4111997-A | ANTIPYRETIC, ANALGESIC, ANTIINFLAMMATORY | TAKEDA CHEMICAL COMPANY, LTD. (JP) | 1978-09-05 | — | — | US | disclosed |
| US-4007225-A | ANTIPYRETIC, ANALGESIC, ANTIINFLAMMATORY | TAKEDA CHEMICAL INDUSTRIES, LTD. (JA) | 1977-02-08 | — | — | US | disclosed |
| US-3953500-A | ANTIPYRETICS, ANALGESICS, ANTIINFLAMMATORY AGENTS | TAKEDA CHEMICAL INDUSTRIES, LTD. (JA) | 1976-04-27 | — | — | US | disclosed |
| JP-S05823640-A | — | — | 0001-01-01 | — | — | JP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250017914-A1 | 6-AZA-QUINOLINE DERIVATIVES AND RELATED USES | TOP2A, TOP2B, UGT2B7 | ALDH1A1 373/4885L3MBTL1 4430/4885LMNA 2740/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.